Thus, the genetic testing of patients who have shown a strong family history of ovarian cancer and breast cancer will be immensely benefitted by monitoring TP53 along with copy number variations and DNA methylation as a biomarker [47,48,49]. This evidence concerns the gene TP53 and ovarian carcinoma.